Brentuximab vedotin is a chimeric monoclonal antibody-drug conjugate that targets CD30, the surface antigen universally expressed in ALCL but also expressed in other lymphomas, including Hodgkin lymphoma and some DLBCLs24,25. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.